<DOC>
	<DOCNO>NCT00052000</DOCNO>
	<brief_summary>This first study MLN2704 administer human . The purpose study determine high dose MLN2704 give safely patient prostate cancer , identify side effect associate take drug . This study also evaluate MLN2704 take ( absorb ) , break ( metabolize ) eliminate ( excrete ) body . This process call pharmacokinetic analysis .</brief_summary>
	<brief_title>A Trial MLN2704 Subjects With Metastatic Androgen Independent Prostate Cancer</brief_title>
	<detailed_description>This Phase 1 open-label dose-escalating trial design determine dose-limiting toxicity ( DLT ) , maximum tolerate dose ( MTD ) pharmacokinetics single dose MLN2704 subject metastatic androgen-independent prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Inclusion Criteria Each subject must meet follow inclusion criterion eligible enrollment study : Histologic diagnosis ( recent remote ) prostate adenocarcinoma Progressive prostate cancer physical exam , image study and/or rise PSA , define presence one following : Progressive tumor lesion ( change size lymph node parenchymal mass physical examination Xray CT scan MRI ) Progressive bone metastasis ( presence new lesion ( ) bone scan ) Progressive PSA level despite castrate level testosterone Patients receive antiandrogen must show progression disease antiandrogen prior enrollment Failed hormonal therapy ( include antiandrogen withdrawal therapy , appropriate ) LHRH ( Luteinizing Hormone–Releasing Hormone ) analog therapy : If subject treat LHRH analog therapy time screen therapy must maintain duration trial . If subject discontinue LHRH therapy prior screening , therapy must discontinue ≥10 week prior enrollment 1 month depot preparation , 24 week 3 month depot preparation , 32 week 4 month depot preparation . Agree use effective method barrier contraception . Effective method barrier contraception include condom spermicidal jelly , diaphragm spermicidal jelly , abstinence . Exclusion Criteria Subjects meeting follow exclusion criterion enrol study : Use corticosteroid and/or adrenal hormone inhibitor within 4 week enrollment Use PCSPES ( herbal supplement ) within 4 week enrollment Prior cytotoxic chemotherapy and/or radiation therapy within 6 week enrollment Use antiandrogen therapy ( e.g. , flutamide , bicalutamide , nilutamide ) within 6 week enrollment Prior monoclonal antibody administration , include Prostacint® Peripheral neuropathy Grade 2 great intensity , define NCI Common Toxicity Criteria ( NCI CTC ) History CNS metastasis , include epidural disease History seizure disorder require active treatment and/or stroke History HIV infection Platelet count ≤100,000/mm3 Absolute neutrophil count ( ANC ) ≤1,500/mm3 Hematocrit ≤30 percent Abnormal coagulation profile ( PT , and/or INR , PTT ) Creatinine clearance &lt; 60 mL/min Serum creatinine &gt; 2.0 mg/dL AST ALT &gt; 1.5 X ULN Bilirubin ( total ) &gt; ULN Serum calcium ≥12.5 mg/dL Active serious infection control antibiotic Active angina pectoris NY Heart Association Class IIIIV heart disease Karnofsky Performance Status &lt; 60 Life expectancy &lt; 6 month Other serious illness ( e ) involve cardiac , respiratory , CNS , renal , hepatic hematological organ system might preclude completion study interfere determination causality adverse effect experience study</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
</DOC>